Cargando…
Bimodality treatment of patients with pelvic adenoid cystic carcinoma with photon intensity-modulated radiotherapy plus carbon ion boost: a case series
BACKGROUND: Treatment of patients with pelvic adenoid cystic carcinoma (ACC) remains a challenge owing to the rarity of the disease, the lack of data, and the relative radioresistance of these tumors. CASE REPORTS: This case series presents the results of three patients with recurrent or inoperable...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875408/ https://www.ncbi.nlm.nih.gov/pubmed/29618938 http://dx.doi.org/10.2147/CMAR.S148395 |
_version_ | 1783310345758048256 |
---|---|
author | Bernhardt, Denise Sterzing, Florian Adeberg, Sebastian Herfarth, Klaus Katayama, Sonja Foerster, Robert Hoerner-Rieber, Juliane König, Laila Debus, Juergen Rieken, Stefan |
author_facet | Bernhardt, Denise Sterzing, Florian Adeberg, Sebastian Herfarth, Klaus Katayama, Sonja Foerster, Robert Hoerner-Rieber, Juliane König, Laila Debus, Juergen Rieken, Stefan |
author_sort | Bernhardt, Denise |
collection | PubMed |
description | BACKGROUND: Treatment of patients with pelvic adenoid cystic carcinoma (ACC) remains a challenge owing to the rarity of the disease, the lack of data, and the relative radioresistance of these tumors. CASE REPORTS: This case series presents the results of three patients with recurrent or inoperable pelvic ACC treated with intensity-modulated radiotherapy (IMRT) plus carbon ion (C12) boost. Patients received C12 therapy at a dose of 3 Gray equivalents (GyE) (relative biological effectiveness [RBE]) per fraction up to 24 GyE RBE, followed by 50 GyE of photon IMRT in 25 fractions. CONCLUSION: IMRT plus C12 ion boost as a definitive or adjuvant treatment for pelvic ACCs seems to be a promising therapeutic option. No unexpected toxicity was detected and the observed toxicity remained consistently low. The initial treatment response is promising and similar to that experienced for head and neck ACCs. |
format | Online Article Text |
id | pubmed-5875408 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-58754082018-04-04 Bimodality treatment of patients with pelvic adenoid cystic carcinoma with photon intensity-modulated radiotherapy plus carbon ion boost: a case series Bernhardt, Denise Sterzing, Florian Adeberg, Sebastian Herfarth, Klaus Katayama, Sonja Foerster, Robert Hoerner-Rieber, Juliane König, Laila Debus, Juergen Rieken, Stefan Cancer Manag Res Case Series BACKGROUND: Treatment of patients with pelvic adenoid cystic carcinoma (ACC) remains a challenge owing to the rarity of the disease, the lack of data, and the relative radioresistance of these tumors. CASE REPORTS: This case series presents the results of three patients with recurrent or inoperable pelvic ACC treated with intensity-modulated radiotherapy (IMRT) plus carbon ion (C12) boost. Patients received C12 therapy at a dose of 3 Gray equivalents (GyE) (relative biological effectiveness [RBE]) per fraction up to 24 GyE RBE, followed by 50 GyE of photon IMRT in 25 fractions. CONCLUSION: IMRT plus C12 ion boost as a definitive or adjuvant treatment for pelvic ACCs seems to be a promising therapeutic option. No unexpected toxicity was detected and the observed toxicity remained consistently low. The initial treatment response is promising and similar to that experienced for head and neck ACCs. Dove Medical Press 2018-03-26 /pmc/articles/PMC5875408/ /pubmed/29618938 http://dx.doi.org/10.2147/CMAR.S148395 Text en © 2018 Bernhardt et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Case Series Bernhardt, Denise Sterzing, Florian Adeberg, Sebastian Herfarth, Klaus Katayama, Sonja Foerster, Robert Hoerner-Rieber, Juliane König, Laila Debus, Juergen Rieken, Stefan Bimodality treatment of patients with pelvic adenoid cystic carcinoma with photon intensity-modulated radiotherapy plus carbon ion boost: a case series |
title | Bimodality treatment of patients with pelvic adenoid cystic carcinoma with photon intensity-modulated radiotherapy plus carbon ion boost: a case series |
title_full | Bimodality treatment of patients with pelvic adenoid cystic carcinoma with photon intensity-modulated radiotherapy plus carbon ion boost: a case series |
title_fullStr | Bimodality treatment of patients with pelvic adenoid cystic carcinoma with photon intensity-modulated radiotherapy plus carbon ion boost: a case series |
title_full_unstemmed | Bimodality treatment of patients with pelvic adenoid cystic carcinoma with photon intensity-modulated radiotherapy plus carbon ion boost: a case series |
title_short | Bimodality treatment of patients with pelvic adenoid cystic carcinoma with photon intensity-modulated radiotherapy plus carbon ion boost: a case series |
title_sort | bimodality treatment of patients with pelvic adenoid cystic carcinoma with photon intensity-modulated radiotherapy plus carbon ion boost: a case series |
topic | Case Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875408/ https://www.ncbi.nlm.nih.gov/pubmed/29618938 http://dx.doi.org/10.2147/CMAR.S148395 |
work_keys_str_mv | AT bernhardtdenise bimodalitytreatmentofpatientswithpelvicadenoidcysticcarcinomawithphotonintensitymodulatedradiotherapypluscarbonionboostacaseseries AT sterzingflorian bimodalitytreatmentofpatientswithpelvicadenoidcysticcarcinomawithphotonintensitymodulatedradiotherapypluscarbonionboostacaseseries AT adebergsebastian bimodalitytreatmentofpatientswithpelvicadenoidcysticcarcinomawithphotonintensitymodulatedradiotherapypluscarbonionboostacaseseries AT herfarthklaus bimodalitytreatmentofpatientswithpelvicadenoidcysticcarcinomawithphotonintensitymodulatedradiotherapypluscarbonionboostacaseseries AT katayamasonja bimodalitytreatmentofpatientswithpelvicadenoidcysticcarcinomawithphotonintensitymodulatedradiotherapypluscarbonionboostacaseseries AT foersterrobert bimodalitytreatmentofpatientswithpelvicadenoidcysticcarcinomawithphotonintensitymodulatedradiotherapypluscarbonionboostacaseseries AT hoernerrieberjuliane bimodalitytreatmentofpatientswithpelvicadenoidcysticcarcinomawithphotonintensitymodulatedradiotherapypluscarbonionboostacaseseries AT koniglaila bimodalitytreatmentofpatientswithpelvicadenoidcysticcarcinomawithphotonintensitymodulatedradiotherapypluscarbonionboostacaseseries AT debusjuergen bimodalitytreatmentofpatientswithpelvicadenoidcysticcarcinomawithphotonintensitymodulatedradiotherapypluscarbonionboostacaseseries AT riekenstefan bimodalitytreatmentofpatientswithpelvicadenoidcysticcarcinomawithphotonintensitymodulatedradiotherapypluscarbonionboostacaseseries |